Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery

14:03
 
Share
 

Manage episode 480436349 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

An interview with:

Andrea Cercek MD, Gastrointestinal Cancer Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York

And:

Ryan B Corcoran MD PhD, Director of the GI Cancer Program, Massachusetts General Hospital Cancer Center, Boston MA

CHICAGO—The Audio Journal of Oncology reports on the neoadjuvant use of programmed cell-death protein 1 (PD-1) immune checkpoint inhibition to give patients whose resectable colorectal cancers express mismatch repair deficiency the option of avoiding surgery. Early results from a phase two trial with the PD-1 blocker dostarlimab were reported at the 2025 Annual Meeting of the American Association for Cancer Research held in Chicago.

At the meeting the Audio Journal’s correspondent Peter Goodwin met up with the study first author, Andrea Cercek MD, a gastrointestinal cancer medical oncologist from Memorial Sloan Kettering Cancer Center in New York.

AACR Abstract title:

“Non operative management of mismatch repair deficient tumors”

  continue reading

51 episodes

Artwork
iconShare
 
Manage episode 480436349 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

An interview with:

Andrea Cercek MD, Gastrointestinal Cancer Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York

And:

Ryan B Corcoran MD PhD, Director of the GI Cancer Program, Massachusetts General Hospital Cancer Center, Boston MA

CHICAGO—The Audio Journal of Oncology reports on the neoadjuvant use of programmed cell-death protein 1 (PD-1) immune checkpoint inhibition to give patients whose resectable colorectal cancers express mismatch repair deficiency the option of avoiding surgery. Early results from a phase two trial with the PD-1 blocker dostarlimab were reported at the 2025 Annual Meeting of the American Association for Cancer Research held in Chicago.

At the meeting the Audio Journal’s correspondent Peter Goodwin met up with the study first author, Andrea Cercek MD, a gastrointestinal cancer medical oncologist from Memorial Sloan Kettering Cancer Center in New York.

AACR Abstract title:

“Non operative management of mismatch repair deficient tumors”

  continue reading

51 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play